Amgen - Product sales + Buyback + Pipeline Opportunity - Boost Confidence
Robust sales growth from its established and newly launched products, returns through payout through a combination of dividend and share buyback, focusing on innovation and geographical expansion through acquisitions, such as, Micromet (MITI), KAI pharma (pvt., US based) and increase its presence in emerging markets (Brazil, Turkey), and divest pipeline products smartly while retaining full rights for a few which have synergies with its recently launched products (AMG 785, AMG 145) make AMGN attractive among its peers. Based on its revised guidance for FY12, sales growth … For more detail, please read our report released on 31st July, 2012, titled, “Product sales + Buyback + Pipeline Opportunity - Boost Confidence”.
